Abstract
This chapter first differentiates the concepts of traditional/complementary medicine and their products. It then briefly introduces the supervision and management systems of the China Food and Drug Administration and the differences between conventional medicine and traditional/complementary medicine products, taking drugs used in traditional Chinese medicine as an example. The chapter analyzes and discusses the global use of and regulatory environment for complementary and integrated medicine, and reviews the current methodological approaches to pharmacovigilance for herbal drugs and traditional medicines. Therefore throughout this chapter are showcased the challenges associated with such products and their rational uses, and the imperfections in the global supervision of such medicines in terms of both the methodology behind monitoring by the spontaneous reporting system (SRS) and additional pharmacovigilance. Finally, suggestions are proposed for measures to enhance pharmacovigilance of herbal and traditional medicines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
WHO (2013) WHO traditional medicine strategy 2014–2023. http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/. Accessed 20 Jun 2017
WHO Traditional medicine: definitions. http://www.who.int/medicines/areas/traditional/definitions/en/. Accessed 20 Jun 2017
Ramzan I, Linek EV (2015) International regulatory status of phytotherapies. Phytothérapie 24:593–634
Pharmacopoeia Commission of the Ministry of Health of the People’s Republic of China (2015) Pharmacopoeia of the People’s Republic of China, vol 1. China Medical Science Press, Beijing
EMA. Herbal medicinal products. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000208.jsp&mid=WC0b01ac05800240cf. Accessed 23 Jun 2017
Gao X, Zhong G (2013) Traditional Chinese pharmacy, 2nd edn. Beijing People Medical Publishing House, Beijing
FDA (2016) Dietary supplement products & ingredients. https://www.fda.gov/Food/DietarySupplements/ProductsIngredients/default.htm. Accessed 23 Jun 2017
FDA (2015) Current good manufacturing practices (CGMPs) for dietary supplements. http://www.fda.gov/Food/GuidanceRegulation/CGMP/ucm079496.htm. Accessed 23 Jun 2017
Safety Reporting Portal. https://www.safetyreporting.hhs.gov/fpsr/WorkflowLoginIO.aspx?metinstance=21DCB60A574A25D878FF89ABA96E9CD95D31EAF5. Accessed 23 Jun 2017
Government of Canada (2017) Food and drug regulations. http://laws.justice.gc.ca/eng/regulations/C.R.C.,_c._870/index.html. Accessed 23 Jun 2017
Government of Canada (2015) Natural and non-prescription health products. https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription.html. Accessed 23 Jun 2017
EMA (2004) Directive 2004/24/EC of the European parliament and of the council. http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2004_24/dir_2004_24_en.pdf. Accessed 23 Jun 2017
Zhang L, Wong YL, He Y et al (2014) Pharmacovigilance in China: current situation, successes and challenges. Drug Saf 37(10):765–770. https://doi.org/10.1007/s40264-014-0222-3
Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4(4):177. https://doi.org/10.3389/fphar.2013.00177
The State Administration of Traditional Chinese Medicine (2011) China. http://www.satcm.gov.cn/1987-2010/start.htm. Accessed 20 Jun 2016
Friesen D (2013) Traditional Chinese Medicine: business blockbuster or false fad? CKGSB Knowledge. http://knowledge.ckgsb.edu.cn/2013/01/08/china/traditional-chinese-medicine-business-blockbuster-or-false-fad/. Accessed 23 Jun 2017
Lindstrom A, Ooyen C, Lynch ME et al (2014) Sales of herbal dietary supplements increase by 7.9% in 2013, marking a decade of rising sales. HerbalGram 103:52–56
NIH (2014) Frequently asked questions: name change. https://nccih.nih.gov/news/name-change-faq. Accessed 23 Jun 2017
UMC (2000) Safety monitoring of medicinal products. https://www.who-umc.org/media/1703/24747.pdf. Accessed 23 Jun 2017
Barnes J (2003) Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 26(12):829–851
UMC (2017) Half a century of pharmacovigilance. https://www.who-umc.org/global-pharmacovigilance/global-pharmacovigilance/half-a-century-of-pharmacovigilance/. Accessed 23 Jun 2017
Edwards IR, Ericsson J (2006) Spontaneous reporting of herbal ADRs: the global experience. Drug Saf 29(4):351–352
Farah MH, Olsson S, Bate J et al (2006) Botanical nomenclature in pharmacovigilance and a recommendation for standardization. Drug Saf 29(11):1023–1029
Bate A, Ericsson J, Farah M (2006) International data mining for signals of herbal ADRs. Drug Saf 29(4):353–354
Farah M, Meyboom R, Ploen M (2008) Acute hypersensitivity reactions to Andrographis paniculata containing products, as reported in international pharmacovigilance. Drug Saf 31(10):885–960
CFDA (2016) 2015 Annual report for National ADR Monitoring. http://www.sfda.gov.cn/WS01/CL0051/158941.html. Accessed 25 Jun 2017
Zhang L, Yan J, Liu X et al (2012) Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol 140(3):519–525
Kalaiselvan V, Saurabh A, Kumar R et al (2015) Adverse reactions to herbal products: an analysis of spontaneous reports in the database of the Pharmacovigilance Programme of India. J Herbal Med 5:48–54
Sareeya W, Wimon S, Vorasith S et al (2014) Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Regul Toxicol Pharmacol 70:407–412
Denney CE, Tsourounis C, Horn AJ (2005) Dietary supplement-related adverse events reported to the California poison control system. Am J Health Syst Pharm 62:1476–1482
Gryzlak BM, Wallace RB, Zimmerman MB et al (2007) National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepidemiol Drug Saf 16:947–957
Shaw D, Graeme L, Pierre D et al (2012) Pharmacovigilance of herbal medicine. J Ethnopharmacol 140(3):513–518
Gardiner P, Sarma D, Low DT et al (2008) The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf 17:962–970
Edwards IR (2014) Adverse drug effects and their clinical management: a personal view. Drug Saf 37:383–390. https://doi.org/10.1007/s40264-014-0167-6
WHO (2009) Report of the regional meeting, World Health Organization. The use of herbal medicines in primary health care. World Health Organization, Regional Office for South-East Asia, India
McRae CA, Agarwal K, Mutimer D et al (2012) Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol 14:559–562
Shaw D (2010) Investigation of liver toxicity of Chinese herbal medicine: pilot case-control study. Drug Saf 33:918–919
Chuang CH, Chang PJ, Hsieh WS et al (2009) Chinese herbal medicine use in Taiwan during pregnancy and the postpartum period: a population-based cohort study. Int J Nurs Stud 46:787–795
Pal SN, Wallberg M, Coulter D et al (2010) Cohort event monitoring: a WHO strategy to complement spontaneous reporting systems. Drug Saf 33(10):939
Saokaew S, Suwankesawong W, Permsuwann U et al (2011) Safety of herbal products in Thailand. Drug Saf 34:339–350
Deng PY, Li QN, Zhu YZ (2005) An analysis of ADR of Puerarin Injection and related risk factors. Chin J Pharmacoepidemiol 14(1):14–24
Deng PY, Zhang L (2008) The post-marketing safety monitoring of puerarin injection (1). Chin J Pharamacovigilance 5(3):136–143
Deng PY, Zhang L (2008) The post-marketing safety monitoring of puerarin injection (2). Chin J Pharamacovigilance 5(4):208–211
Deng JX, Yu JY, Yuan ZM (2012) Post-marketing safety reevaluation of Shengmai Injection. China Licensed Pharmacist 9(12):11–16
Yu JY, Deng JX, Ma GY et al (2014) Post-marketing safety reassessment of Shenqifuzheng Injection. China Licensed Pharmacist 11(1):13–15
Du W, Levine M, Wang L et al (2007) Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. Can J Clin Pharmacol 14:e40–e44
Guo DH, Chen C, Ma L et al (2014) Analysis and evaluation of the active monitoring data from five hospitals by ADE warning systems for hospitalized patients. Chin J Drug Appl Monit 11(6):368–371
Yang HC, Iqbal U, Nguyen PA et al (2016) An automated technique to identify potential inappropriate traditional Chinese medicine (TCM) prescriptions. Pharmacoepidemiol Drug Saf 25(4):422–430. https://doi.org/10.1002/pds.3976
World Health Organisation (2004) WHO guidelines on safety monitoring of herbal. Medicines in pharmacovigilance systems. WHO, WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, Geneva. http://apps.who.int/medicinedocs/documents/s7148e/s7148e.pdf. Accessed 20 Apr 2015
Simon LS (2002) Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 61.(Suppl.2:ii88–ii89
Buch MH, Aletaha D, Emery P et al (2011) Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 70:886–890
Walji R, Boon H, Barnes J et al (2009) Adverse event reporting for herbal medicines: a result of market forces. Healthcare Policy 4(4):77–90
Ministry of Health and China Food and Drug Administration (2011) Adverse drug reaction reporting and monitoring provision. http://app1.sfda.gov.cn/WS01/CL0288/62621.html. Accessed 7 Jun 2017
CFDA (2009) Notice for doing well in the reevaluation of TCM injections. http://www.sda.gov.cn/WS01/CL0055/39880.html. Accessed 20 Jun 2017
CFDA (2010) Notice for publication the 7 principals for technical guideline on TCM injection safety re-evaluation concerning production process, quality control clinical study and so on. http://www.sda.gov.cn/WS01/CL0055/54917_2.html. Accessed 20 Jun 2017
Liao X, Xie Y, Yang W, Chang Y (2014) The significance of introducing registry study in the post marketing safety research for Chinese medicine pharmacy. Chin J Integr Tradit West Med 34(3):261–266
Xia L, Li JH, Zhao K et al (2015) Incidence and in-hospital mortality of acute aortic dissection in China: analysis of China Health Insurance Research (CHIRA) Data 2011. Geriatr Cardiol 12(5):502–506
Zhang Y, Cheng Y, Feng Y et al (2015) A systematic review of publications based on electronic medical records or medicare systems and related databases in China. ISPE’s 9th Asian Conference on Pharmacoepidemiology, Bangkok, Thailand
Chinese Medicine Board of Australia (CMBA) (2014) About us. http://www.chinesemedicineboard.gov.au/About.aspx. Accessed 20 Jun 2017
CMBA (2012) Chinese Medicine Board Newsletter, Issue 1, October, 2012
CMBA (2015) Guidelines for safe Chinese herbal medicine practice. http://www.chinesemedicineboard.gov.au/Codes-Guidelines/Guidelines-for-safe-practice.aspx. Accessed 20 Jun 2017
Guo D, Wu W, Ye M et al (2015) A holistic approach to the quality control of traditional Chinese medicines. Science 347(6219 Suppl):S29–S31
Williamson E, Chan K, Xu Q et al (2015) Evaluating the safety of herbal medicines: integrated toxicological approaches. Science 347(6219 Suppl):S47–S49
Yu Y, Hu S, Li G et al (2014) Comparative effectiveness of Di’ao Xin Xue Kang capsule and compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep 14(4):7058. https://doi.org/10.1038/srep07058
Zhang L, Yang XH, Deng YY (2009) Liver damage related to Polygonum multiflorumand its preparations: domestic literature review and analysis. China J Chin Mater Med 34(18):2414–2418
Skalli S, Bencheikh RS (2015) Pharmacovigilance of herbal medicines in Africa: questionnaire study. J Ethnopharmacol 171:99–108. https://doi.org/10.1016/j.jep.2015.05.033
Chen SP, Ng SW, Poon WT et al (2012) Aconite poisoning over 5 years: a case series in Hong Kong and lessons towards herbal safety. Drug Saf 35(7):575–587. https://doi.org/10.2165/11597470-000000000-00000
Pratt N, Chan EW, Choi NK et al (2015) Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf 24(8):858–864
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zhang, L. (2018). Pharmacovigilance of Herbal and Traditional Medicines. In: Bate, A. (eds) Evidence-Based Pharmacovigilance. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8818-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8818-1_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8816-7
Online ISBN: 978-1-4939-8818-1
eBook Packages: Springer Protocols